

Population 2013

34 million

Estimates of TB burden * 2013	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.78 (0.016–3)	2.3 (0.05–8.8)
Mortality (HIV+TB only)	0 (-)	0 (-)
Prevalence (includes HIV+TB)	25 (12–44)	75 (35–129)
Incidence (includes HIV+TB)	15 (13–17)	45 (39–50)
Incidence (HIV+TB only)		
Case detection, all forms (%)	57 (50–65)	

Estimates of MDR-TB burden * 2013	New	Retreatment
% of TB cases with MDR-TB	3.7 (2.5–4.9)	20 (13–27)
MDR-TB cases among notified pulmonary TB cases	180 (120–240)	130 (85–170)

TB case notifications 2013	New **	Relapse
Pulmonary, bacteriologically confirmed	2 738	302
Pulmonary, clinically diagnosed	2 240	
Extrapulmonary	3 274	

Total new and relapse	8 554
Previously treated, excluding relapses	329
Total cases notified	8 883

Among 8 554 new and relapse cases:

671 (8%) cases aged under 15 years; male:female ratio: 1.0

Reported cases of RR-/MDR-TB 2013	New	Retreatment	Total **
Cases tested for RR-/MDR-TB	3 241 (118%)	382 (61%)	3 623
Laboratory-confirmed RR-/MDR-TB cases			167
Patients started on MDR-TB treatment			84

TB/HIV 2013	Number	(%)
TB patients with known HIV status	3 017	(34)
HIV-positive TB patients	0	(0)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	0	
HIV-positive TB patients on antiretroviral therapy (ART)	0	
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

Treatment success rate	(%)
New and relapse cases registered in 2012	91
Previously treated cases, excluding relapse, registered in 2012	81
HIV-positive TB cases, all types, registered in 2012	50
RR-/MDR-TB cases started on second-line treatment in 2011	64
XDR-TB cases started on second-line treatment in 2011	


Laboratories 2013	
Smear (per 100 000 population)	0.8
Culture (per 5 million population)	1.2
Drug susceptibility testing (per 5 million population)	0.1
Sites performing Xpert MTB/RIF	13
Is second-line drug susceptibility testing available?	Yes, in country

Financing TB control 2014	
National TB programme budget (US\$ millions)	27
% Funded domestically	88%
% Funded internationally	8%
% Unfunded	4%

* Ranges represent uncertainty intervals


** Includes cases with unknown previous TB treatment history

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population)




Prevalence

(Rate per 100 000 population per year)




Notified (new and relapse) Incidence
Incidence (HIV+TB only)

(Number of patients)




HIV-positive TB patients
on CPT on ART

Treatment success rate (%)



New Retreatment
New and relapse Retreatment, excluding relapse
HIV-positive RR-/MDR-TB XDR-TB

Total budget (US\$ millions)



Funded domestically Funded internationally
Unfunded